New Drug Application submitted to FDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis

The submission for this first-in-class, oral therapy that acts locally in gut to inhibit the sodium hydrogen exchanger, is supported by 3 RCTS in >1000 patients that showed reduced phosphate levels, as monotherapy and as part of a dual mechanism approach with phosphate binders.


Biospace Inc.